Proapoptotic BID is required for myeloid homeostasis and tumor suppression

  1. Sandra S. Zinkel1,
  2. Christy C. Ong1,
  3. David O. Ferguson2,
  4. Hiromi Iwasaki3,
  5. Koichi Akashi3,
  6. Roderick T. Bronson3,
  7. Jeffery L. Kutok3,
  8. Frederick W. Alt2, and
  9. Stanley J. Korsmeyer1,4
  1. 1Howard Hughes Medical Institute, Departments of Pathology and Medicine, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; 2Howard Hughes Medical Institute, Division of Immunology, Boston Children's Hospital, Center for Blood Research, Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA; 3Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115, USA

Abstract

The proper expansion and contraction of hematopoietic cells requires tight regulation of cell death. BID, a “BH3-only” molecule, amplifies death receptor signals connecting the extrinsic to intrinsic pathways by triggering the mitochondrial pathway of apoptosis.Bid-deficient mice, as they age, spontaneously develop a myeloproliferative disorder, which progresses from myeloid hyperplasia to a fatal, clonal malignancy closely resembling chronic myelomonocytic leukemia (CMML). Thus, an apoptotic defect can result in myeloid leukemogenesis. Premalignant Bid−/− myeloid precursor cells are resistant to death receptor-induced apoptosis. Furthermore, a competitive reconstitution assay demonstrates thatBid-deficient long-term repopulating cells give rise to expanded myelomonocytic cells in vivo. Surprisingly, a single BH3-only molecule operating in the extrinsic death receptor pathway proved essential in vivo for physiologic cell death required to maintain myeloid homeostasis. Moreover, progression to CMML indicates that an upstream BH3-only molecule, BID, is required to suppress tumorigenesis.

Keywords

Footnotes

  • 4 Corresponding author.

  • E-MAIL stanley_korsmeyer{at}dfci.harvard.edu; FAX (617) 632-6401.

  • Article and publication are at http://www.genesdev.org/cgi/doi/10.1101/gad.1045603.

    • Received September 27, 2002.
    • Accepted November 15, 2002.
| Table of Contents

Life Science Alliance